AffaMed Therapeutics merging with EverInsight

14 October 2020

AffaMed Therapeutics today announced a definitive merger agreement with fellow Shanghai, China-based biopharmaceutical company EverInsight Therapeutics.

This merger brings together complementary businesses to expand AffaMed’s advanced portfolio of existing assets, adding EverInsight’s pipeline of innovative therapeutic candidates in CNS and ophthalmology and further strengthening the company’s global R&D capabilities. The combined company, which will retain the AffaMed Therapeutics name and the entity, will focus on the development of therapeutics for ophthalmologic and CNS disorders in Greater China and beyond.

The two companies were both incubated by CBC Group (formerly known as C-Bridge Capital) and have established partnerships and licensing agreements with leading global biopharmaceutical companies.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK